Ascendis Pharma A (ASND) Debt to Equity: 2021-2024
- Ascendis Pharma A's Debt to Equity fell 80.09% to -$7.79 in Q4 2024 from the same period last year, while for Dec 2024 it was -$7.79, marking a year-over-year decrease of 80.09%. This contributed to the annual value of -$7.79 for FY2024, which is 80.09% down from last year.
- Ascendis Pharma A's Debt to Equity amounted to -$7.79 in Q4 2024, which was down 80.09% from -$4.32 recorded in Q4 2023.
- In the past 5 years, Ascendis Pharma A's Debt to Equity ranged from a high of $1.52 in Q4 2022 and a low of -$7.79 during Q4 2024.
- Moreover, its 3-year median value for Debt to Equity was -$4.32 (2023), whereas its average is -$3.53.
- As far as peak fluctuations go, Ascendis Pharma A's Debt to Equity surged by 1,176.12% in 2022, and later crashed by 385.30% in 2023.
- Ascendis Pharma A's Debt to Equity (Quarterly) stood at $0.12 in 2021, then soared by 1,176.12% to $1.52 in 2022, then slumped by 385.30% to -$4.32 in 2023, then slumped by 80.09% to -$7.79 in 2024.
- Its Debt to Equity was -$7.79 in Q4 2024, compared to -$4.32 in Q4 2023 and $1.52 in Q4 2022.
